Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968

---

Search results

• Journal article
  Rawson TM, Al-Hassan M, Brzeska-Trafny I, Morkowska A, Jauneikaite E, Saman R, Donaldson H, Davies Fet al., 2025,

  Comment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?

  , Journal of Antimicrobial Chemotherapy, Vol: 80, Pages: 1462-1464, ISSN: 0305-7453
  • Publisher Web Link
  • Cite
• Journal article
  Dodds IL, Watts EC, Schuster M, Buscaill P, Tumas Y, Holton NJ, Song S, Stuttmann J, Joosten MHAJ, Bozkurt T, van der Hoorn RALet al., 2025,

  Immunity gene silencing increases transient protein expression in Nicotiana benthamiana

  , Plant Biotechnology Journal, Vol: 23, Pages: 1768-1770, ISSN: 1467-7644
  • Publisher Web Link
  • Cite
• Journal article
  Carter C, Torre IB, Blackburn S, Nwankwo L, Semple T, Rawal B, Armstrong-James D, Patel PH, Shah Aet al., 2025,

  Real-world effectiveness of biologic therapy in allergic bronchopulmonary aspergillosis

  , The Journal of Allergy and Clinical Immunology: In Practice, Vol: 13, Pages: 1094-1102.e1, ISSN: 2213-2198

  BackgroundAllergic bronchopulmonary aspergillosis (ABPA) is characterized by a severe hypersensitivity reaction to Aspergillus species. Current treatment relies on oral corticosteroids (OCS) and triazole antifungal therapy, but there is increasing evidence of the benefits of biologic therapies targeting type 2 inflammatory pathways.ObjectiveTo assess the real-world effectiveness of biologic therapies in patients with ABPA.MethodsWe performed a large retrospective single-center analysis of patients with ABPA as defined by the modified International Society for Human and Animal Mycology (ISHAM) criteria between 2014 and 2022. Baseline characteristics were recorded. Clinical outcomes were assessed at 12 months after commencement of a biologic including symptom scores, exacerbation frequency, corticosteroid use, and multidisciplinary team consensus of effectiveness.ResultsA total of 74 patients received a biologic, of whom 32% (n = 24) received anti-IgE therapy, 65% (n = 48) anti-IL5/5Rα therapy, and 3% (n = 2) anti-IL4-Rα therapy. Of the total, 65% (n = 48) patients were deemed to have a successful response at 12 months with a ≥50% reduction in OCS use and 35% (n = 26) stopped or changed biologic during the follow-up period because of failed clinical response (n = 21), side effects (n = 4), or medical comorbidities (n = 1). There was a significant reduction in the 6-item Asthma Control Questionnaire score (P < .0001), exacerbation rate over 12 months (P < .0001), and maintenance OCS use (P = .0173). Univariate analysis revealed that mucus plugging was associated with nonresponse to biologic therapy (P = .0189).ConclusionBiologic therapies are effective in a number of patients with ABPA. However, further prospective clinical trials are required to determine the effectiveness and which phenotypes likely to respond. These data nevertheless increase the evidence base for biologics in ABPA.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Ogawa H, Uchida Y, Patarin J, Enjuto LE, Ito Ket al., 2025,

  Viscoelastic characteristics of spontaneous sputum obtained from patients with chronic productive cough in comparison to bronchial asthma

  , RESPIRATORY INVESTIGATION, Vol: 63, Pages: 459-466, ISSN: 2212-5345
  • Cite
• Journal article
  Zhou Y, Sun M-L, Lin L, Ledesma-Amaro R, Wang K, Ji X-J, Huang Het al., 2025,

  Dynamic regulation combined with systematic metabolic engineering for high-level palmitoleic acid accumulation in oleaginous yeast

  , METABOLIC ENGINEERING, Vol: 89, Pages: 33-46, ISSN: 1096-7176
  • Cite
  • Citations: 4
• Journal article
  Smith DJF, Teng NMY, Denneny EK, Mehta P, Stanel SC, Blaikley JF, Chambers RC, Chaudhuri N, Garfield B, Garner JL, George PM, Ghai P, Kon OM, Li Y, Man WD-C, Porter JC, Quinn V, Rivera-Ortega P, Ross C, Segal LN, Walker SA, Wu BG, Lloyd CM, Stewart I, Jenkins RG, Molyneaux PLet al., 2025,

  The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.

  , ERJ open research, Vol: 11, Pages: 826-2024, ISSN: 2312-0541

  <h4>Introduction</h4>Up to 11% of patients are left with residual lung abnormalities following COVID-19 infection. It is unclear whether these changes resolve over time or progress to fibrosis. The airway microbiome is altered in interstitial lung disease, potentially contributing to pathogenesis and disease progression. We hypothesised that the airway microbiome in patients with post-COVID-19 residual lung abnormalities may be altered.<h4>Methods</h4>The POST COVID-19 interstitial lung DiseasE (POSTCODE) study recruited subjects with post-COVID-19 residual lung abnormalities for bronchoscopy. 16S ribosomal RNA gene amplicon sequencing was performed on DNA extracted from bronchoalveolar lavage fluid and compared with that from patients with idiopathic pulmonary fibrosis, fibrotic hypersensitivity pneumonitis and control subjects.<h4>Results</h4>28 subjects with post-COVID-19 residual lung abnormalities were recruited an average of 11 months after infection. No significant associations were found between the lower airway microbiome or bacterial burden and disease severity or trajectory. There was no difference in bacterial burden between post-COVID-19 patients and interstitial lung disease or control subjects. Furthermore, no differences in microbial composition were observed between these patients and those with fibrotic hypersensitivity pneumonitis or controls. However, compared with idiopathic pulmonary fibrosis, there was an increased abundance of <i>Streptococcus</i> and higher α-diversity in subjects with post-COVID-19 residual lung abnormalities.<h4>Conclusions</h4>The microbiome and bacterial burden in the lower airways of subjects with post-COVID-19 residual lung abnormalities do not differ from those of controls. The microbiome differs from idiopathic pulmonary fibrosis. This, and the absence of associations between microbial features and disease severity or clinical outcomes, suggests that t

  • Abstract
  • Cite
• Report
  Coppens L, Bamezai S, Polizzi K, Frost G, Collins T, Carmichael R, Ledesma Amaro R, Corujo Simon Eet al., 2025,

  Microbial foods as a sustainable, healthy and resilient source of nutrients for the UK

  , Publisher: IMSE Institute
  • Cite
• Journal article
  Baker JR, Daly L, Hassibi S, Kimura G, Nishimoto Y, Kizawa Y, Ito Ket al., 2025,

  Senolytic therapy reduces inflammation in epithelial cells from COPD patients and in smoke-exposure mice

  , FRONTIERS IN MEDICINE, Vol: 12
  • Cite
  • Citations: 1
• Journal article
  Chen H, Song F, Wang B, Huang H, Luo Y, Han X, He H, Lin S, Wan L, Huang Z, Fu Z, Ledesma-Amaro R, Yin D, Mao H, He L, Yang T, Chen Z, Ma Y, Xue EY, Wan Y, Mao Cet al., 2025,

  Ultrasensitive detection of clinical pathogens through a target-amplification-free collateral-cleavage-enhancing CRISPR-CasΦ tool

  , NATURE COMMUNICATIONS, Vol: 16
  • Cite
  • Citations: 11
• Journal article
  Chen H, Jiang J, Ledesma-Amaro R, 2025,

  Microalgae-based vaccines for aquaculture

  , Trends in Biotechnology, ISSN: 0167-7799

  Microalgae-based oral vaccines bolster aquaculture by sustainably enhancing fish immunity and curbing disease outbreaks. Here, we introduce the rational design of vaccine antigens and discuss the oral delivery and immune benefits of microalgae-based vaccines. We expect advances in synthetic biology and fish immune metabolism to drive microalgae-based vaccine innovation.

  • Abstract
  • Publisher Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.